Glaxosmithkline (Finland)

Glaxosmithkline (Finland)

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Glaxosmithkline (Finland), Finland, covering academic research published from 2003 to 2023. Read More.


Open Access Percentage

55%


Total
Publications

103


Total Open
Publications

57


Total
Citations

3.1K


Open Access
Percentage

55%


Total
Publications

103


Total Open
Publications

57


Total
Citations

3.1K

Wikipedia

Website

download

Breakdown

30% 20% 5% 45%

Publisher Open

30%

Both

20%

Other Platform Open

5%

Closed

45%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0246810121416Total Publications
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

17%OA Journal

OA Journal 17%

9

Hybrid 50%

26

No Guarantees 33%

17

Other Platform Open

Domain 54%

14

Institution 42%

11

Other Internet 19%

5

Preprint 15%

4

Public 15%

4

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
14
Europe PMC
Domain
6
Semantic Scholar
Public
3
University of Turku - UTUPub
Institution
2
University of Dundee - Discovery Research Portal
Institution
2
The University of Glasgow - Enlighten: Publications
Institution
2
medRxiv
Preprint
2
Le Centre pour la Communication Scientifique Directe - HAL - Université de Nantes
Institution
2
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
2
Julkari - STM:n Hallinnonalan avoin julkaisuarkisto
Other Internet
2
1 / 3

Data updated 13 August 2024

Share

Share

Share